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? Hypersensitivity (HSR) to abacavir (ABC) occurs in approximately 
5-8% of patients, usually within the first 6 weeks of treatment, and 
necessitates immediate and permanent ABC discontinuation.1
? Clinical presentation is non-specific and involves combinations of 
symptoms from several categories of organ involvement (fever, skin 
rash, gastrointestinal [GI], constitutional, respiratory, etc).
? A high degree of HSR over-diagnosis has been observed, with rates of 
2–7% reported in patients not receiving ABC in blinded comparative
studies of ABC-containing products.
? ABC HSR is strongly linked to carriage of the major histocompatibility
complex Class I allele HLA-B*5701.2,3
? Epicutaneous patch testing (EPT) has been used as a research tool to 
confirm immunologically mediated ABC reactions in subjects with a 
previous clinical diagnosis of HSR.4
? Assessing the characteristics of ABC HSR diagnoses according to 
HLA-B*5701 status and/or subsequent EPT result may help to refine 
the HSR phenotype.
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? PREDICT-1 (CNA106030)5 was a large, blinded multinational study 
that randomised 1956 ABC-naïve subjects 1:1 to receive prospective 
HLA-B*5701 screening (screening arm) or to a control arm with 
retrospective HLA-B*5701 assessment at study end.
? HLA-B*5701 positive subjects in the screening arm did not receive ABC 
in the study. All others received an abacavir-containing regimen for 
6 weeks with investigators and patients blinded as to study arm
? Subjects with a clinical diagnosis of ABC HSR returned for EPT visits 
6–10 weeks after drug discontinuation.
? Clinically diagnosed HSR during the observation period and clinically 
diagnosed HSR with a positive EPT result were the two co-primary 
endpoints of the study.
? Post-hoc exploratory analyses were undertaken to assess the 
relationship between HSR symptoms and HLA-B*5701 status, EPT 
status, introduction of a new NNRTI and use of a concomitant PI using 
a Fishers exact test.
Table 1. HLA-B*5701 Status and EPT Results in 
Subjects with Clinically Diagnosed ABC HSR
? These clinical data from the PREDICT-1 study suggest that 
patients with immunologically mediated abacavir HSR, as 
evidenced by carriage of HLA-B*5701 and a positive EPT result:
? develop symptomatic HSR whose median onset occurs 
earlier (though not significantly so) and which presents 
within a shorter time period (within 3 weeks of abacavir
initiation).
? develop a presentation that is significantly more likely to 
involve fever and symptoms from at least 3 categories of 
organ involvement.
? However, overlap still exists between HSR symptom categories 
and time of onset for diagnoses between subjects with positive 
and negative EPT results, suggesting that refining the criteria for 
HSR case ascertainment based on these findings might reduce 
clinical over-diagnosis but would not eliminate it.
? This symptomatic overlap and the existence of six HLA-B*5701-
positive clinical diagnoses of HSR without a positive EPT result
underscores that avoiding ABC in prospectively screened, HLA-
B*5701-positive individuals – as shown in PREDICT-15 – is likely 
to reduce HSR diagnosis and misdiagnosis more effectively than 
modifying the case ascertainment process.
? All positive EPT results were obtained following a clinical diagnosis of 
HSR in subjects who were HLA-B*5701-positive. 
? Of 29 HLA-B*5701-positive HSR diagnoses with EPT results, 23/29 gave 
a positive EPT result and 6/29 were EPT negative. It is not clear whether 
these six negative EPT results were due to operator error, initial clinical 
misdiagnosis of HSR or an intrinsic false-negative rate for the EPT 
procedure. 
? This discordance cautions that while a positive EPT-result can confirm a 
prior immunologically mediated HSR event, a negative result cannot be 
used as confirmation that no HSR has occurred. For this reason, EPT 
was used in PREDICT-1 only to refine a statistical endpoint and not as a 
tool of patient management. ABC was not re-initiated in EPT-negative 
subjects.
? Time to onset of symptoms and the frequency distribution of these 
symptoms differed between clinical HSR diagnoses with a positive EPT 
result and those with a negative result.  All HSR diagnoses with a 
positive EPT result showed onset of symptoms within 19 days of ABC 
initiation.
? HSR diagnoses in subjects who were HLA-B*5701 positive and EPT 
positive tended to occur earlier and had a significantly higher incidence 
of fever and symptoms from at least three classes. These prospective 
findings are consistent with recent data from retrospective analyses in 
which EPT was used to refine HSR case ascertainment.6,7 The high 
incidence of the combination of fever with rash and constitutional 
symptoms in cases with positive EPT results observed here has not 
been previously reported.
? For those HSR diagnoses with negative EPT results, the observation 
that rash occurred more in subjects taking a new NNRTI is consistent 
with the known confounding effect of NNRTI-associated rashes on HSR 
case ascertainment
? The significance of the higher incidence of respiratory symptoms also 
observed in these patients is uncertain.
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*Six subjects with clinically diagnosed HSR did not undergo EPT for reasons of refusal (n=4), 
loss to follow-up (n=1) and failure to attend EPT visits (n=1). One of these six subjects was 
HLA-B*5701-positive.
? Of patients who had a clinical diagnosis of HSR, 32% (30/93) were 
HLA-B*5701-positive. All but one of these underwent an EPT. 
? Positive EPT results were obtained in 26% (23/87) of cases tested.
? Six HLA-B*5701-positive subjects with a clinical HSR diagnosis gave a 
negative EPT result.
? All subjects with a positive EPT result were HLA-B*5701-positive. 
Figure 1. Days to Onset of Symptoms for 
Clinically Diagnosed ABC HSR According to 
Subsequent EPT Result 
? The median time to onset of HSR symptoms was 8 days [IQR 5-10] for 
diagnoses with a positive EPT result, versus 11 days [IQR 4-14.5] for 
those with a negative EPT result. No HSR diagnosis with a positive EPT 
result presented after day 19 of treatment.
? Similar results were observed for HSR diagnoses in HLA-B*5701-
positive subjects versus those who were HLA-B*5701 negative 
(median 8.5 days to onset [IQR 6-11] versus 10 days [IQR 3-14]).
? These differences were not statistically significant.
Figure 2. Summary of HSR Symptom 
Categories by Subsequent EPT Result
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Figure 3: Combinations of HSR Symptom 
Categories by Subsequent EPT Result
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? Fever was present in 91% (21/23) of HSR diagnoses with a positive EPT 
result versus only 39% (25/64) of diagnoses that gave a negative EPT 
result (P < 0.0001).
? 91% (21/23) of HSR diagnoses with a positive EPT result involved
symptoms from 3 or more categories, versus only 58% (37/64) of those 
without a positive EPT result (P = 0.0048).
? Amongst all HSR diagnoses that involved symptoms from 3 or more 
categories, fever with rash and constitutional symptoms were present 
with or without other symptoms in 65% (15/23) of diagnoses with a 
positive EPT result versus only 16% (10/64) of those without (P < 0.0001).
? Similar, but less compelling results were observed for HSR diagnoses in 
HLA-B*5701-positive subjects versus those who were HLA-B*5701-
negative (Fever 80% [24/30] versus 40% [25/63]; P < 0.001. Three or more 
categories 83% [25/30] versus 57% [36/63]; P = 0.0208).
Figure 4: Impact of New NNRTI Initiation on 
Clinically Diagnosed HSR Symptoms in 
Subjects with a Negative EPT Result 
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? For HSR diagnoses that gave negative EPT results, rash and respiratory 
symptoms were significantly more common in those who initiated a new 
NNRTI during the study compared with those who did not (Rash: 93% 
[14/15] versus 57% [28/49]; P = 0.0158. Respiratory: 67% [10/15] versus
27% [13/49]; P = 0.0126). Conversely, GI symptoms were more common 
in those who did not initiate a new NNRTI (27% [4/15] versus 61% 
[30/49]; P = 0.0392)
? Similar trends were observed for HSR diagnoses in HLA-B*5701-
negative patients who did or did not initiate a new NNRTI, although in 
these patients only the difference in respiratory symptoms reached 
statistical significance at the P < 0.05 level (60% [9/15] of those who took 
a new NNRTI versus 25% [12/48] of those who did not; P = 0.0308)
? No difference in GI symptom incidence was observed for EPT-negative 
HSR diagnoses in those who did or did not receive concurrent protease 
inhibitors during the study (data not shown)
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